Skip to content
Dr. Homey

Dr. Homey

The doctor is in.

Primary Menu
  • Home
  • Exterior Design
  • Interior Design
  • Handy Tips
  • Investments & Crypto
  • Parenting
  • Contact Us
  • Home
  • Dr Homey's Favorites
  • What this means for the direct-to-consumer genetic testing market

What this means for the direct-to-consumer genetic testing market

Steve Gilford February 24, 2023 7 min read
87
23andme richard branson 600m ipo nasdaqrosenbaumcnbc

Direct-to-consumer (DTC) genetic testing has become increasingly popular in recent years, with several companies offering customers personalised and targeted genetic tests. These tests can assess an individual’s predisposition to specific medical conditions or predict their ancestry, gender, or traits. The growing market is also making accessible a variety of tests that examine genes associated with health and fitness, nutrition, mental health and even drug responses.

The increasing availability of these tests has profoundly impacted the direct-to-consumer genetic testing market. Consumers now have more access to information about their DNA than ever before and are exposed to a wider range of data points that enable them to make informed decisions about their health. This access further changes the future of genomics by furthering research into key areas such as public health, technology, ethical considerations and accuracy/quality control.

As the industry continues to evolve and the regulatory landscape adjusts accordingly, DTC genetic testing is becoming an important tool for individuals seeking personalised information about themselves to make empowered choices concerning their well-being.

Overview of the direct-to-consumer genetic testing market

The direct-to-consumer genetic testing market is a rapidly growing sector with a great potential for growth in the coming years. This market includes companies such as 23andMe, which recently announced it is going public via Richard Branson’s Special Purpose Acquisition Company (SPAC). This move has huge implications for the direct-to-consumer genetic testing market and could increase competition and opportunities for existing players.

In this article, we will discuss the current state of the direct-to-consumer genetic testing market and the potential impacts of 23andMe’s move.

23andMe to go public via Richard Branson’s SPAC

23andMe is a direct-to-consumer genetic testing service that provides customers personalised information about their health, traits and ancestry. Originally launched in 2006, 23andMe has become the direct-to-consumer genetic testing market leader. The company provides customers access to more than 95 health, traits and ancestry reports on its website and mobile app.

23andme branson spac 600m ipo nasdaqrosenbaumcnbc

23andMe’s user base has experienced tremendous growth over the years, with more than 10 million users worldwide. Among these users, 6 million have accessed their health and trait reports. In contrast, 3 million have taken advantage of 23andMe’s Ancestry Reports featuring a unique breakdown of ethnic regions and populations based on the customer’s DNA profile.

In addition to providing access to general genetic reports, 23andMe also offers customers access to its Health Risks report—a comprehensive assessment of an individual’s potential risks for several diseases or conditions based on scientific studies conducted over several years. With these types of offerings, 23andMe has become an industry leader in both genomic analysis data services and providing comprehensive insights into individuals’ genetics and general population genetics, which can then be used for disease research and development of new medical treatments.

How 23andMe’s move to go public affects the direct-to-consumer genetic testing market

The direct-to-consumer genetic testing market is rapidly evolving and 23andMe’s recent move to go public changes the landscape in a big way. This move by 23andMe gives the company access to the resources and capital that will help them expand their services, research, and product offerings. It also provides other direct-to-consumer genetic testing market players with a model for going public or staying independent but still scaling up operations.

In turn, this could spur more competition as players in the space look to build out their capabilities and become more profitable. Increased competition could mean better costs for customers who want genetic testing services such as health reports, ancestry information, or personalised recommendations.

At the same time, it’s important to note that 23andMe still faces considerable regulatory hurdles before they can officially become a publicly traded company — mainly fulfilling FDA requirements for their health-related reports which have been reported as recently as January 2021. Such regulatory requirements have raised concerns around consumer data privacy, potentially affecting how existing and new players operate within this space. Moreover, as 23andMe works towards becoming a listed company on one of America’s biggest stock exchanges, the ripples in this market are far from done yet — with consumers most likely having more choices than ever before when it comes to direct-to-consumer genetic tests.

The Impact of 23andMe’s Move

23andMe’s decision to go public via Richard Branson’s SPAC is a major development for the direct-to-consumer genetic testing market. It signals the increasing growth and acceptance of the sector, and will likely spur further investments and innovations in the space.

In this article, we will discuss the impact of this move, and what it could mean for the future of direct-to-consumer genetic testing.

Increased competition in the market

The direct-to-consumer (DTC) genetic testing market has recently seen an influx of new players and competition, spurring innovation and lowered prices. 23andMe’s move into the space is a major development. The company is entering the market with many competitive advantages, including public recognition, several investment rounds totaling hundreds of millions in capital, and vast amounts of funding for research activities.

23andme branson 600m ipo nasdaqrosenbaumcnbc

The impact on the DTC genetic testing market can be seen in multiple areas. For starters, the presence of established players such as 23andMe is bringing more attention to personalised health monitoring technology and fueling its rapid development. As a result, consumers now have more choices. For example, 23andMe carries tests that offer real-time notification when you are at risk for developing conditions like Type 2 diabetes; this data was unavailable just a few years ago. Additionally, because there are now more options on the market, consumers are paying less than before; this creates an overall healthier marketplace where available offerings are continually enhanced through increased competition.

In addition to lowering prices, the entrance of big names such as 23andMe into the market has provided more assurance to customers who may have hesitated to use lesser-known products due to concerns over accuracy or results interpretation from smaller companies which often lack expert oversight or scientific knowledge. The presence of trusted industry giants increases consumer confidence and will undoubtedly increase uptake for DTC testing products.

Increased investment in the market

In 2018, the direct-to-consumer genetic testing leader 23andMe announced its collaboration with GlaxoSmithKline and, in November 2019, Roche holding took a majority stake in the company. This move has increased investment in the market, paving the way for more personalised healthcare offerings.

As 23andMe expands its offerings to include not just ancestry but also health and wellness information, other players in the market are also capitalising on this trend. Companies such as Color Genomics, Helix and Invitae have launched direct-to-consumer genetic tests with special emphasis on conditions such as cancer screening.

Furthermore, studies suggest that customers would be willing to pay for medically approved direct-to-consumer genetic tests if provided with an easy checkout process and access to counselling services or additional support. This suggests that there is potential for growth within this particular healthcare sector even beyond what is currently available.

By leveraging partnerships with pharmaceutical companies such as GlaxoSmithKline and Roche Holding Ltd., 23andMe has been able to access larger pools of investment and expertise which will help them further develop their product range. This increase in investment is likely to catalyse increased competition between players in the direct-to-consumer genetic testing market and a wider range of offerings available to consumers interested in learning more about their genetics.

Increased regulation of the market

In January of 2021, 23andMe announced that they were significantly reducing the scope of its direct-to-consumer DNA testing services, citing “regulatory challenges” as the reason for their decision to stop offering health reports to customers. This move will likely have far-reaching implications for the direct-to-consumer genetic testing market, given that 23andMe is one of the most popular and trusted companies in this space.

23andme richard spac 600m ipo nasdaqrosenbaumcnbc

The decreased availability of health reports from 23andMe means increased regulation for other companies in this market. Likely, government regulators may now require more stringent restrictions on how these services can be advertised and sold to consumers. For example, companies may need to provide more information about potential risks of each test before allowing a consumer to purchase one. Furthermore, companies will also be required to adhere to guidelines on how personal data obtained from these tests can be used or stored by third parties.

These changes are likely to impact existing providers of direct-to-consumer genetic testing services and those looking to enter the market in the future. The increased regulation could make it more difficult or expensive for smaller companies just starting in this space, as additional costs will be associated with meeting all regulatory requirements. Further, increased oversight could lead to higher prices for consumers looking for these services and less availability, depending on how strictly authorities enforce regulations.

tags = genetics testing company 23andMe , Virgin Group founder Richard Branson, 23andme richard 600m ipo nasdaqrosenbaumcnbc, 23andme richard branson ipo nasdaqrosenbaumcnbc, 23andme spac 600m ipo nasdaqrosenbaumcnbc

Steve Gilford

Steve is a home design and renovator from Pennsylvania, who loves finding creative solutions to solve challenging home design problems. Steve went to the University of Pennsylvania with a double major in Architecture and Civil Engineering. After graduating, he worked as an independent contractor doing interior renovations, before starting his own business specializing job site management and project management on larger projects including entire house designs.

See author's posts

Continue Reading

Previous: Mollenkopf succeeds Paul Jacobs as CEO
Next: The 23andMe and Virgin Group Merger

Related Stories

The history of the Meris botnet rostelecom meris ddos windowscimpanu therecord
7 min read

The history of the Meris botnet

February 24, 2023 107
The benefits of using artificial intelligence for data labeling labelbox 110m vision fund ceo labelboxcaiforbes
8 min read

The benefits of using artificial intelligence for data labeling

February 24, 2023 132
What are some of the challenges faced by Labelbox? labelbox 110m softbank vision fund labelboxcaiforbes
7 min read

What are some of the challenges faced by Labelbox?

February 24, 2023 103

exterior design articles

Where to Use the Stainless Steel Access Doors
3 min read

Where to Use the Stainless Steel Access Doors

Steve Gilford January 11, 2023 318
If you’re planning to install stainless steel access doors in your building, it would be more beneficial...
Read More
Five Things to Know Before You Begin an Expensive Backyard Makeover

Five Things to Know Before You Begin an Expensive Backyard Makeover

December 5, 2022
The Right Time of Year to Build a Pergola

The Right Time of Year to Build a Pergola

October 19, 2022
Escape the Heat With a Patio Umbrella

Escape the Heat With a Patio Umbrella

September 27, 2022
Step by Step DIY Guide on How to Build a Solid Wood Door

Step by Step DIY Guide on How to Build a Solid Wood Door

August 17, 2022
  • Privacy Policy
  • Terms & Conditions
  • About Us
© 2022 Drhomey.com
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT